Darzalex March Continues with EU Approval

The latest approval for Johnson & Johnson's monoclonal antibody therapy Darzalex in multiple myeloma keeps the product firmly on course as a much-needed new option in relapsed/refractory patients but competition in the market is hotting up all the time.

chemist

The European Commission has now granted conditional approval to Janssen-Cilag's (Johnson & Johnson) first-in-class anti-CD38 antibody Darzalex (daratumumab; licensed form Genmab) for use in melanoma following a CHMP positive opinion in April. (Also see "Accelerated EU Committee Nod for J&J/Genmab's Darzalex " - Scrip, 1 April, 2016.)

The approval, the second for the novel product after it was given an earlier-than-expected go-ahead by the US FDA last...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip